Respiratory illnesses are taking center stage this season, with flu and Covid-19 cases dominating media coverage and public concern. However, there's another respiratory virus that's causing a stir - Respiratory Syncytial Virus (RSV). The Centers for Disease Control and Prevention (CDC) reports that RSV cases are on the rise across the country, especially among young children.
According to data from the Center for Infectious Disease Research & Policy (CIDRAP) at the University of Minnesota, emergency department visits and hospital admissions for children aged four and under have increased. The Pan American Health Organization has also issued a warning, stating that RSV activity is gradually increasing, which could put additional strain on healthcare systems, especially with the ongoing flu cases.
RSV is a common respiratory illness that typically causes mild, cold-like symptoms. However, it can be severe, especially for infants, young children, and older adults. The CDC estimates that over 100,000 older Americans and 58,000 infants and young children are hospitalized annually due to RSV.
In a surprising development, U.S. health authorities approved two types of immunizations for RSV in mid-2023. These include vaccines for older adults and pregnant individuals to protect their newborns, as well as a monoclonal antibody injection for newborns and infants.
A recent survey conducted by the Annenberg Public Policy Center (APPC) of the University of Pennsylvania reveals an increased awareness of these RSV immunizations among the public. The survey, which included 1,637 U.S. adults, found that about 6 in 10 respondents would recommend the vaccine or antibody injections to the groups suggested by the CDC, indicating a positive shift in public perception.
But here's where it gets controversial...
This rise in awareness and recommendation comes at a time when U.S. health officials, under the leadership of vaccine critic Robert F. Kennedy Jr., have made significant changes to childhood vaccination guidelines. In 2023, the CDC recommended RSV immunization for newborns and infants, either through a maternal RSV vaccine during pregnancy or a monoclonal antibody injection. However, in January 2026, U.S. health authorities reduced the number of regular childhood vaccinations from 17 to 11, with RSV immunization not included in this count.
An HHS spokesman clarified that these high-risk groups for RSV immunization include all healthy children whose mothers were not vaccinated against RSV during pregnancy. This means that the guidelines for newborns have effectively remained the same - either vaccinate during pregnancy or provide the monoclonal antibody injection to infants.
The CDC also recommends the antibody injection for certain young children at an increased risk of severe RSV disease.
So, what does this mean for the growing knowledge of RSV vaccines?
The CDC recommends RSV vaccination for adults aged 75 and older, and for those aged 50-74 who are at an increased risk of severe RSV. The survey findings show an increase in awareness of these immunizations, with a majority of adults now aware of the FDA-approved vaccine for older adults. Similarly, there's a growing familiarity with the maternal vaccine to protect newborns, although there's been a recent decline in awareness compared to previous years.
And this is the part most people miss...
A majority of Americans surveyed expressed a likelihood to recommend the RSV vaccine and monoclonal antibody injection as per CDC guidelines. Nearly two-thirds said they would recommend the vaccine to older adults and those at risk, which is a significant increase from previous years. Similarly, there's a growing willingness to recommend the vaccine to pregnant individuals and the antibody injection to parents of newborns, especially if the mother wasn't vaccinated during pregnancy.
Ken Winneg, managing director of survey research at APPC, commented, "It's encouraging to see this increase in recommending RSV interventions. It's crucial for healthcare professionals and public health officials to communicate the value of these immunizations."
Most U.S. adults surveyed believe that getting the RSV vaccine is safer than contracting the virus itself. This perception has strengthened over time, with a five-point increase in those who believe it's safer for older adults and pregnant individuals to get vaccinated.
This survey data, collected by SSRS, an independent market research company, provides valuable insights into the public's understanding and perception of RSV immunizations. It highlights the growing awareness and acceptance of these interventions, which could have a significant impact on public health and the management of respiratory illnesses.
